DexCom Inc (DXCM)vsRoyal Bank of Canada (RY)
DXCM
DexCom Inc
$73.74
+1.94%
HEALTHCARE · Cap: $28.45B
RY
Royal Bank of Canada
$189.53
-27.25%
FINANCIAL SERVICES · Cap: $262.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Royal Bank of Canada generates 1216% more annual revenue ($63.42B vs $4.82B). RY leads profitability with a 33.1% profit margin vs 19.3%. DXCM appears more attractively valued with a PEG of 1.38. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
RY
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.8%
Fair Value
$669.08
Current Price
$73.74
$595.34 discount
Intrinsic value data unavailable for RY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Mega-cap, among the largest globally
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 46.2%
Generating 37.3B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.6x book value
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : RY
The strongest argument for RY centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 33.1% and operating margin at 46.2%.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : RY
The primary concerns for RY are PEG Ratio.
Key Dynamics to Monitor
DXCM carries more volatility with a beta of 1.40 — expect wider price swings.
DXCM is growing revenue faster at 15.0% — sustainability is the question.
RY generates stronger free cash flow (37.3B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DXCM scores higher overall (72/100 vs 66/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Royal Bank of Canada
FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA
Royal Bank of Canada is a globally diversified financial services company. The company is headquartered in Toronto, Canada.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?